Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE4
INTERVENTIONAL
2017-07-31
2023-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy Study of Atorvastatin to Treat Variant Angina
NCT00620204
Effects of Short Term, High Dose Atorvastatin Therapy on Periprocedural Myonecrosis and Platelet Inhibition After Percutaneous Coronary Intervention (PCI)
NCT00979940
Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome
NCT01372839
Effect of Atorvastatin Administration Before Primary Percutaneous Coronary Intervention
NCT00610870
The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm
NCT01674686
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Atorvastatin
20mg QD
Atorvastatin
20mg QD
Placebo
Placebo
Placebo drug will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Atorvastatin
20mg QD
Placebo
Placebo drug will be administered.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Vasospastic angina
* LDL less than 160mg/dl
* Written consent
Exclusion Criteria
* History of percutaneous coronary intervention
* Cerebrovascular diseases or peripheral
* Dyslipidemia required statin therapy
* Heart failure, arrhythmogenic right ventricular dysplasia, hypertrophic cardiomyopathy, akinesia or aneurysm on left ventricular wall, anomaly of coronary artery
* NYHA III and IV
* Arrhythmia
* Primary cardiac electrical diseases
* Cardiac pacemaker or implantable defibrillator
* Pregnancy or breast feeding
* Life expectancy less than 2 years
19 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CardioVascular Research Foundation, Korea
OTHER
Seung-Jung Park
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seung-Jung Park
professor of medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Asan Medical Center
Seoul, Songpa-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AMCCV2016-11
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.